Clinical trials: EGFR Gene Overexpression
Carcinoma, Non-Small-Cell Lung
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
This will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway.
- Trial name
- NCT00294762
- Testing
- Tarceva, carboplatin, paclitaxel
- Where
- 43 sites in United States, United Kingdom
- Volunteers
- 143 people
- Sponsor
- OSI Pharmaceuticals
Advanced Refractory Solid Tumors, EGFR Gene Overexpression
Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-Positive
This phase II trial evaluates the combination of Becotatug Vedotin (MRG003), an EGFR-targeting ADC, and Pucotenlimab (HX008), a PD-1 inhibitor, in patients with high EGFR expressing advanced refractory solid tumors.
- Trial name
- NCT07712029
- Testing
- Becotatug Vedotin, Pucotenlimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Tianjin Medical University Second Hospital
Stomach Neoplasms
Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin…
- Trial name
- HER2 (NCT02136836)
- Where
- South Korea
- Volunteers
- 860 people
- Sponsor
- Yonsei University
Glioblastoma, Brain Cancer
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Primary brain cancer kills up to 10,000 Americans a year. These brain tumors are typically treated by surgery, radiation therapy and chemotherapy, either individually or in combination.
- Conditions
- Glioblastoma, Brain Cancer, Brain Neoplasm, Brain Tumor
- Trial name
- NCT02861898
- Testing
- Intra-arterial Cetuximab, Intra-arterial Mannitol
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Northwell Health